Ulipristal acetate
| Clinical data | |
|---|---|
| Trade names | Ella, EllaOne, Esmya, others |
| Other names | CDB-2914; 11β-[4-(Dimethylamino)phenyl]-17α-acetoxy-19-norpregna-4,9-diene-3,20-dione |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Drug class | Selective progesterone receptor modulator[1] |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Nearly 100% |
| Protein binding | 96.7–99.5% |
| Metabolism | Likely CYP3A4 |
| Elimination half-life | 32 hours[1] |
| Excretion | ca. 90% with feces |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.207.349 |
| Chemical and physical data | |
| Formula | C30H37NO4 |
| Molar mass | 475.629 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Ulipristal acetate, sold under the brand name Ella among others, is a medication used for emergency contraception (birth control) and uterine fibroids.[1][7][8] As emergency contraception it should be used within 120 hours of vaginally penetrating intercourse.[1] For fibroids it may be taken for up to six months.[9] It is taken by mouth.[1]
Common side effects include headache, nausea, feeling tired, and abdominal pain.[1] It should not be used in women who are already pregnant.[1] It is in the selective progesterone receptor modulator (SPRM) class of medications.[1] It works by preventing the effects of progesterone, therefore preventing ovulation but not affecting fertilization or implantation.[10][11]
Ulipristal acetate was approved for medical use in the United States in 2010.[1] It is on the World Health Organization's List of Essential Medicines.[12]
- ^ a b c d e f g h i "Ulipristal Acetate". The American Society of Health-System Pharmacists. Archived from the original on 10 December 2017. Retrieved 8 December 2017.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "ellaOne 30 mg - Summary of Product Characteristics (SmPC)". (emc). 1 July 2021. Archived from the original on 8 December 2023. Retrieved 28 February 2022.
- ^ "Esmya 5 mg Tablets (ulipristal acetate) - Summary of Product Characteristics (SmPC)". (emc). 17 February 2021. Retrieved 28 February 2022.
- ^ "Ella- ulipristal acetate tablet". DailyMed. 1 November 2023. Retrieved 26 September 2024.
- ^ Cite error: The named reference
ellaOne EPARwas invoked but never defined (see the help page). - ^ Garnock-Jones KP, Duggan ST (October 2017). "Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids". Drugs. 77 (15): 1665–1675. doi:10.1007/s40265-017-0812-3. PMID 28900897. S2CID 207489367.
- ^ "Ulipristal - Drugs.com". Drugs.com. Archived from the original on 14 December 2017. Retrieved 14 December 2017.
- ^ British National Formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 510, 560. ISBN 9780857111562.
- ^ Likis FE (2016). Women's Gynecologic Health. Jones & Bartlett Publishers. p. 243. ISBN 9781284076028. Archived from the original on 10 December 2017.
- ^ Li HW, Resche-Rigon M, Bagchi IC, Gemzell-Danielsson K, Glasier A (November 2019). "Does ulipristal acetate emergency contraception (ella®) interfere with implantation?". Contraception. 100 (5): 386–390. doi:10.1016/j.contraception.2019.07.140. PMID 31351035. S2CID 198952998.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.